KYOTO MEDICAL PLANNING

What KYOTO MEDICAL PLANNING does

KYOTO MEDICAL PLANNING (株式会社京都医療設計) is a privately held Japanese medical-device company headquartered in Yamashina-ku, Kyoto City, founded in 1985 and operating with 5,001-10,000 employees across four licensed offices (Kyoto, Osaka, Nara, Tokyo). The company operates an unusually vertically integrated model spanning a regional dealer business in the Kansai region (Kyoto, Shiga, Osaka, Nara) selling catheters and examination equipment, a national general distributor (総代理店) network, and proprietary product R&D, manufacturing, regulatory approval (薬事申請), and domestic clinical-trial operations. As of September 1, 2023, the company merged with Nikke Medical (株式会社ニッケ・メディカル) within the Nikke Co., Ltd. corporate group, consolidating R&D, manufacturing, and sales capability.

The company's product portfolio centers on bioabsorbable medical materials. Its proprietary technology includes the Igaki-Tamai Stent (the world's first bioabsorbable stent, developed from the early 1990s and commercialized in Europe as the lower-limb REMEDY in 2007), Genocel® gelatin fiber non-woven fabric (offered in sheet, block, and powder forms for cell culture, tissue engineering, and drug discovery support), Pawdre® polyglycolic-acid absorbable tissue reinforcement sheets used in Japanese surgery for approximately 30 years, and the Dome Port™ all-silicone multiport for laparoscopic surgery launched nationwide in December 2023. The newest platform extension, the Genocel® Cardio Plate launched in February 2025, enables functional maturation and bright-field contraction evaluation of iPS-derived cardiomyocytes for cardiotoxicity testing. The company also distributes complementary devices including MedLinket disposable EEG and SpO2 sensors and OxyTrue A mobile capnography equipment under general-agent agreements.

Kyoto Medical Planning's revenue model is anchored on one-time sale of proprietary medical devices and distributed third-party products across five business segments: cardiology/cardiothoracic surgery (PCI catheters, bioabsorbable stents), regenerative medicine and research institutions (Genocel scaffolds), general surgery (Pawdre, Dome Port), ENT (tracheostomy tubes, nasal packing), and medical examination departments (sensors and monitoring equipment). Distribution runs through a direct Kansai regional dealer network, a national general-agent channel established in 1993, and direct proprietary-product sales; the 2025 launch of Genocel Cardio Plate added Cosmo Bio as a research-channel distributor. Marketing leans heavily on participation in major Japanese medical congresses and a public paper archive documenting peer-reviewed validation of Genocel across journals including Tissue Engineering Parts A and C, Scientific Reports, and Nature Communications. Pricing is not publicly disclosed and no revenue figures are reported.

Name

KYOTO MEDICAL PLANNING

Legal name

株式会社京都医療設計

Website

https://kyoto-mp.co.jp

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

KYOTO MEDICAL PLANNING is a Kyoto-based Japanese medical device company that researches, develops, manufactures, and sells bioabsorbable medical products (stents, gelatin scaffolds, PGA sheets, surgical multiports) and distributes catheters and examination equipment to hospitals, clinics, and research institutions across Japan via a regionally integrated dealer, national distributor, and direct-sales model.

Ownership category

akta.pro rank

Product category

Medical Devices (bioabsorbable materials)

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) (2820), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL)

akta.pro secondary industries

Medical & Food-Contact Specialty Compounds (IMANABAK), Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers) (IMALAIAB)

Keywords

• Bioabsorbable medical devices
• Medical device distribution
• Regenerative medicine materials
• Surgical reinforcement materials
• Catheter and examination equipment

Headquarters

HQ city

Kyoto

HQ country

Japan

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical device dealer sales: Sale of catheters and examination equipment to medical institutions through dealer network in Kansai region. The company handles over 10,000 product items including PCI catheters, surgical and examination instruments.
2. National distribution (総代理店): Distribution of proprietary and licensed medical devices nationwide, including bioabsorbable suture reinforcement materials, high-performance mobile inspection equipment (CapnoTrue, OxyTrue A), and other medical devices. Started in 1993.
3. Proprietary product manufacturing and sales: In-house development, manufacturing, quality control, regulatory approval (薬事申請), and domestic clinical trials of proprietary medical devices including bioabsorbable stents and gelatin fiber non-woven fabrics (Genocel).

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

KYOTO MEDICAL PLANNING develops, manufactures, and distributes proprietary medical devices built around bioabsorbable (bioresorbable) materials. Its portfolio includes the world's first bioabsorbable coronary and lower-limb stent (Igaki-Tamai Stent / REMEDY), Genocel gelatin fiber non-woven scaffolds for cell culture and regenerative medicine, PGA absorbable tissue reinforcement (Pawdre), silicone multiport devices for laparoscopic surgery (Dome Port), and ENT/examination equipment. Beyond its own products, the company operates as a regional dealer (Kansai) and national distributor of catheters, surgical, and examination equipment to Japanese medical institutions.

Product overview

KYOTO MEDICAL PLANNING offers a diversified portfolio of medical devices spanning research materials, surgical products, ENT (ear/nose/throat) devices, and examination equipment. Their core offerings include Genocel® gelatin fiber substrates for cell culture research, the bioabsorbable Igaki-Tanai Stent/REMEDY™ system, PGA-based tissue reinforcement sheets (Pawdre®), surgical multiports (Dome Port™), and various diagnostic sensors including EEG and SpO2 monitors. The company operates as a combined dealer, distributor, and R&D manufacturer with a focus on bioabsorbable medical materials.

Differentiator

Problem solved

Functional benefit

Brands

• Genocel®: Cell culture用的ゼラチン繊維不織布 (gelatin fiber nonwoven fabric) available in sheet, block, and powder forms for research and medical applications including drug delivery matrices and tissue engineering scaffolds.
• Genocel® Cardio Plate
• Pawdre®
• Dome Port™
• Igaki-Tamai Stent®

Products and services

• Genocel (ジェノセル) Cell culture gelatin fiber substrate available in sheet, powder, and block forms. Used as a scaffold for 3D cell culture, tissue engineering, drug delivery, and regenerative medicine research. Maintains shape during culture; supports cell infiltration beyond 1 mm and heterogeneous cell stacking.
• Genocel Cardio Plate (ジェノセル カーディオ プレート) Cardiomyocyte evaluation plate using customized gelatin fiber nonwoven fabric (Genocel). Promotes maturation of cardiomyocytes through orientation on gelatin fibers and mechanical stimulation via cell contraction; enables simple contraction evaluation via bright-field observation; supports sarcomere development to ~2.0-2.2 µm.
• Igaki-Tamai Stent / REMEDY (イガキ・タナイ ステント) World's first bioabsorbable peripheral vascular / coronary stent. Mesh tube inserted into tubular structures (blood vessels, trachea, esophagus, duodenum, large intestine, bile duct) that expands the lumen and decomposes after serving its therapeutic purpose, avoiding long-term complications of permanent metallic stents. Developed in collaboration with Dr. Hideo Tamai of Shiga Prefecture Medical Center.
• Pawdre (ポードレ) Sheet-type tissue reinforcement material made of polyglycolic acid (PGA). Decomposes into water and carbon dioxide through hydrolysis and is absorbed in the body; eliminates foreign body residue from reinforcement procedures.
• Dome Port (ドームポート) All-silicone transparent multiport for laparoscopic surgery. Flexible silicone material follows complex, three-dimensional device operations, providing performance not available in conventional rigid laparoscopic ports.
• Kyoto Dispo Tracheostomy Tube (京ディスポ 気管切開チューブ) Disposable tracheostomy tube for ENT (ear, nose, and throat) applications in Japanese hospitals.
• Cenefom Nasal Packing (セネフォーム ネーザルパッキング) Nasal packing product for ENT (ear, nose, throat) applications.
• Calnon (カルノン) ENT product for ear, nose, and throat medical applications.
• Medlinket Disposable EEG Sensor (Medlinket ディスポEEGセンサ) Disposable EEG sensor for neurological examination and monitoring.
• MedLinket SpO2 Sensor (MedLinket SpO2センサ) SpO2 sensor for blood oxygen saturation monitoring in clinical examination.
• OxyTrue A (オキシトゥルー A) / CapnoTrue Mobile high-performance examination equipment for capnography and oxygen monitoring.
• COMPASS guide N Navigation guide system for medical procedures.
• Multi-holder (マルチホルダー) Multi-holder device for surgical applications.

Quantifiable outcome

• Bile duct epithelial regeneration achieved within 3 months using Genocel tube (Uemoto et al., Tissue Engineering Part A, 2022)
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Nikkei (日本毛織株式会社)coreOEM/ Whitelabel/ Licensing Partner · 1 September 2023Kyoto Medical Planning merged with Nikkei Medical (株式会社ニッケ・ナチュラル) on September 1, 2023, to form a new corporate group. The merged entity develops, manufactures, and sells medical devices. Nikkei's group logo appears on Kyoto Medical Planning's website. Genocel Cardio Plate is jointly manufactured and sold by Nikkei and Kyoto Medical Planning. The companies operate as a unified corporate group under the 'people and earth friendly' philosophy.
• Cosmo Bio Co., Ltd. (コスモ・バイオ株式会社)coreChannel Partner/ Reseller/ DistributorCosmo Bio is listed as the sales distributor for Genocel Cardio Plate (research use product). Genocel Cardio Plate is sold as '心筋細胞評価用ゼラチン繊維不織布プレート Genocel Cardio plate' with approval number 研究用商材, manufactured by Nikkei and Kyoto Medical Planning and distributed by Cosmo Bio.
• Shiga Prefecture Medical Center (滋賀県立成人病センター)coreStrategic or Co-development PartnerCollaboration between Kyoto Medical Planning founder Kei Igaki and Dr. Hideo Tamai (then Deputy Director of Shiga Prefecture Medical Center) led to the development of the world's first bioabsorbable stent. This clinical collaboration was foundational to the IGAKI-TANAI STENT development that took approximately 10 years to reach clinical research stage.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Terumo Corporation: Terumo is one of Japan's largest medical device companies with a strong cardiovascular intervention portfolio (catheters, stents, blood management). KMP pioneered PCI introduction to Japan and operates a Kansai catheter dealership that competes with Terumo's broader national cardiovascular franchise. Both share Japan-centric manufacturing and physician-relationship GTM models.
• Nipro Corporation: Nipro is a diversified Japanese medical device manufacturer with strong positions in dialysis, interventional radiology, and surgical products, plus pharmaceutical packaging. Comparable to KMP in its combined manufacturer-distributor-dealer model in Japan, though Nipro operates at significantly larger global scale.
• Abbott Laboratories (Vascular Division):

Direct peers

• Asahi Intecc Co., Ltd. Asahi Intecc is a Japanese specialist in guidewires, catheters, and peripheral intervention devices, with proprietary polymer processing technology and PCI/peripheral sales channels. It is the closest direct competitor to KMP's Kansai catheter dealership and shares KMP's hybrid manufacturer-distributor structure, though Asahi has substantially more global commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kyoto-medical-planning-co-ltd-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KYOTO MEDICAL PLANNING